Predictive Oncology (NASDAQ:POAI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Predictive Oncology Inc. (NASDAQ:POAI) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $11.04 and traded as low as $5.83. Predictive Oncology shares last traded at $6.14, with a volume of 66,744 shares changing hands.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Wall Street Zen lowered Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Predictive Oncology in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Predictive Oncology Trading Down 4.4%

The firm has a 50-day moving average of $6.79 and a two-hundred day moving average of $11.04. The firm has a market capitalization of $20.84 million, a P/E ratio of -0.45 and a beta of 1.35.

Predictive Oncology (NASDAQ:POAI) last issued its earnings results on Friday, November 14th. The medical instruments supplier reported ($4.52) EPS for the quarter, missing the consensus estimate of ($1.35) by ($3.17). The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $1.50 million. Predictive Oncology had a negative return on equity of 732.73% and a negative net margin of 5,065.23%. On average, sell-side analysts anticipate that Predictive Oncology Inc. will post -2.08 EPS for the current fiscal year.

Predictive Oncology Company Profile

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.